search
Back to results

Frailty in Liver Transplant Exercise (FLEX) Trial (FLEX)

Primary Purpose

Frailty, Liver Transplants

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Exercise intervention
Sponsored by
Milton S. Hershey Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Frailty

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adults age ≥18 or ≤75 years
  • Frail as defined by a LFI score of >4.5
  • Under evaluation or listed for liver transplant

Exclusion Criteria:

  • Active cardiac symptoms (e.g., chest pain, shortness of breath at rest, palpitations)
  • Positive response to Get Active Questionnaire (GAQ) (validated activity questionnaire that indicates if exercise is unsafe)
  • Institutionalized/prisoner
  • Severe medical comorbidities/psychiatric illness at the discretion of the Study Principal Investigator (PI)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Exercise intervention

    Control

    Arm Description

    Private supervised strength training exercise (e.g., body weight or dumbbell exercises) will occur in the Cancer Center Exercise Medicine Unit or the Hershey Center for Applied Research (HCAR) two days a week. In addition, subjects will be instructed to exercise on their own, at home, three days a week doing 30 minutes of moderate intensity aerobic exercise (e.g., walking at 45-55% maximum heart rate determined by the formula max heart rate = 220bpm - 0.64*age in years).

    Subjects in the control condition will be instructed to continue their medical care at the discretion of their treating medical professional and to maintain their current exercise level. Weekly phone calls will be performed to ensure adherence to the protocol (no changes in activity). Subjects will report to Penn State on a monthly basis for interim history and physical to confirm self-reports. Subjects will also be given a FitBit ChargeHR3 and downloaded data review will be performed monthly at the in-person visits.

    Outcomes

    Primary Outcome Measures

    Number of participants able to complete the trial
    Defined as 50% of subjects completing >80% of the sessions.
    Incidence of Treatment-Emergent Adverse Events as assessed by GCP guidelines
    This study aims to examine the incidence of adverse events. If exercise in frail liver transplant candidates is safe. 5% serious adverse events or fewer will deem the trial as safe. If more than 5% serious adverse events occur, the trial is determined to be unsafe.
    Rate of enrollment
    Net enrollment rates, which are calculated by dividing the number of subjects approached by the number of subjects that enroll in the trial. The work with the ongoing NASHFit and completed ENACT Trials and the work of others performing exercise-based trials in patients with cirrhosis(50) has established >50% enrollment of subjects approached as a threshold of acceptability.

    Secondary Outcome Measures

    Full Information

    First Posted
    December 11, 2019
    Last Updated
    June 25, 2021
    Sponsor
    Milton S. Hershey Medical Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04200846
    Brief Title
    Frailty in Liver Transplant Exercise (FLEX) Trial
    Acronym
    FLEX
    Official Title
    Frailty in Liver Transplant Exercise (FLEX) Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2021
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    No funding
    Study Start Date
    July 1, 2021 (Anticipated)
    Primary Completion Date
    February 1, 2022 (Anticipated)
    Study Completion Date
    December 1, 2022 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Milton S. Hershey Medical Center

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Frailty is common in patients with end-stage liver disease. It's characterized by reduced strength, low endurance and reduced physical function. While exercise intervention can improve frailty in geriatric patients without liver disease, whether or not exercise intervention can improve frailty in liver transplant candidates remains unknown.
    Detailed Description
    The long-term goal is to better understand how exercise impacts frailty in order to identify treatments that can improve both patient-oriented outcomes and access to liver transplantation for end-stage liver disease patients. The specific objective of this proposal is to generate pilot feasibility data required for future multicenter R01 application to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) which will test the novel central hypothesis that exercise improves frailty and lessens waiting-list mortality. Additionally, another goal of the study is to establish an optimal frailty tool for liver transplant candidates.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Frailty, Liver Transplants

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    An interventional pilot trial will be performed with 21 randomized subjects who are aged 18-75 years who are frail according to the LFI to a 3-month exercise intervention (n=14) versus standard of care (n=7) with no change in activity.
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Exercise intervention
    Arm Type
    Experimental
    Arm Description
    Private supervised strength training exercise (e.g., body weight or dumbbell exercises) will occur in the Cancer Center Exercise Medicine Unit or the Hershey Center for Applied Research (HCAR) two days a week. In addition, subjects will be instructed to exercise on their own, at home, three days a week doing 30 minutes of moderate intensity aerobic exercise (e.g., walking at 45-55% maximum heart rate determined by the formula max heart rate = 220bpm - 0.64*age in years).
    Arm Title
    Control
    Arm Type
    No Intervention
    Arm Description
    Subjects in the control condition will be instructed to continue their medical care at the discretion of their treating medical professional and to maintain their current exercise level. Weekly phone calls will be performed to ensure adherence to the protocol (no changes in activity). Subjects will report to Penn State on a monthly basis for interim history and physical to confirm self-reports. Subjects will also be given a FitBit ChargeHR3 and downloaded data review will be performed monthly at the in-person visits.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Exercise intervention
    Intervention Description
    Subjects in this group will be asked to exercise 5 days a week. Two days on-site with an Exercise Physiologist and the other 3 days at home.
    Primary Outcome Measure Information:
    Title
    Number of participants able to complete the trial
    Description
    Defined as 50% of subjects completing >80% of the sessions.
    Time Frame
    up to 52 weeks
    Title
    Incidence of Treatment-Emergent Adverse Events as assessed by GCP guidelines
    Description
    This study aims to examine the incidence of adverse events. If exercise in frail liver transplant candidates is safe. 5% serious adverse events or fewer will deem the trial as safe. If more than 5% serious adverse events occur, the trial is determined to be unsafe.
    Time Frame
    up to 52 weeks
    Title
    Rate of enrollment
    Description
    Net enrollment rates, which are calculated by dividing the number of subjects approached by the number of subjects that enroll in the trial. The work with the ongoing NASHFit and completed ENACT Trials and the work of others performing exercise-based trials in patients with cirrhosis(50) has established >50% enrollment of subjects approached as a threshold of acceptability.
    Time Frame
    up to 52 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Adults age ≥18 or ≤75 years Frail as defined by a LFI score of >4.5 Under evaluation or listed for liver transplant Exclusion Criteria: Active cardiac symptoms (e.g., chest pain, shortness of breath at rest, palpitations) Positive response to Get Active Questionnaire (GAQ) (validated activity questionnaire that indicates if exercise is unsafe) Institutionalized/prisoner Severe medical comorbidities/psychiatric illness at the discretion of the Study Principal Investigator (PI)

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Frailty in Liver Transplant Exercise (FLEX) Trial

    We'll reach out to this number within 24 hrs